Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496274 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01496274 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 63 participants.
The verdict
NCT01496274, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.
Interventions
- BIOLOGICAL rIX-FP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496274
The ClinicalTrials.gov registry entry for NCT01496274 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rIX-FP is the first listed.
NCT01496274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496274 about?
NCT01496274 is a clinical study titled "A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B". This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.
What is the current status of trial NCT01496274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2012-02.
What interventions are being tested in trial NCT01496274?
The interventions under investigation include: rIX-FP (BIOLOGICAL).
Who is sponsoring clinical trial NCT01496274?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.